Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) — Market Cap & Net Worth
Market Cap & Net Worth: Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) has a market capitalization of $86.66 Million ($86.66 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19825 globally and #4451 in its home market, demonstrating a -6.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Insight Molecular Diagnostics Inc.'s stock price $5.32 by its total outstanding shares 28599300 (28.60 Million). Review Insight Molecular Diagnostics Inc. debt and liabilities to assess the company's total debt and financial obligations.
Insight Molecular Diagnostics Inc. Market Cap History: 2025 to 2026
Insight Molecular Diagnostics Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $214.49 Million to $152.15 Million (0.00% CAGR).
Insight Molecular Diagnostics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Insight Molecular Diagnostics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of IMDX by Market Capitalization
Companies near Insight Molecular Diagnostics Inc. in the global market cap rankings as of June 17, 2026.
Key companies related to Insight Molecular Diagnostics Inc. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Insight Molecular Diagnostics Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Insight Molecular Diagnostics Inc.'s market cap moved from $214.49 Million to $ 152.15 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $152.15 Million | -29.07% |
| 2025 | $214.49 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Insight Molecular Diagnostics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $86.66 Million USD |
| MoneyControl | $86.66 Million USD |
| MarketWatch | $86.66 Million USD |
| marketcap.company | $86.66 Million USD |
| Reuters | $86.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more